Endo became Endo Pharmaceuticals as a result of a management buyout from DuPont Merck in 1997. Endo Pharmaceuticals enhance their financial flexibility by outsourcing many of their functions, including manufacturing. The company's strategy is to continue to strengthen its position as a market leader in pain management, while opportunistically pursuing other markets, especially those with a complementary therapeutic or physician base. The element of their strategy include: capitalizing on their established brand names through focused marketing and promotion, developing proprietary products and selected generics and acquiring and in-licensing complementary products, compounds and technologies.